Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 23;30(1):363.
doi: 10.3892/ol.2025.15109. eCollection 2025 Jul.

Efficacy of transarterial chemoembolization-hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy in hepatocellular carcinoma with portal vein tumor thrombosis

Xunbo Hou  1 , Qiannan Xu  2 , Linan Yin  1 , Huiwen Wang  1 , Juan Wu  3 , Bowen Liu  1 , Dongfeng He  1 , Ruibao Liu  1
Affiliations

Efficacy of transarterial chemoembolization-hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy in hepatocellular carcinoma with portal vein tumor thrombosis

Xunbo Hou et al. Oncol Lett. .

Abstract

Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) presents a notable therapeutic challenge. The efficacy of transarterial chemoembolization (TACE) combined with hepatic arterial infusion chemotherapy (HAIC) and systemic therapy using tyrosine kinase inhibitor and programmed cell death protein 1 inhibitor has not been fully explored. In the present study, the clinical data from 251 patients with HCC and PVTT treated at Harbin Medical University Cancer Hospital (Harbin, China) between January 2021 and December 2022 were retrospectively analyzed. Patients were divided into four groups: TACE-HAIC + lenvatinib + camrelizumab (Group 1; n=16), TACE + lenvatinib + camrelizumab (Group 2; n=90), HAIC + lenvatinib + camrelizumab (Group 3; n=102) and TACE alone (Group 4; n=43). Clinical data included demographics, preoperative indices, tumor characteristics, medical history, performance status, liver function, pre-treatment α-fetoprotein levels and adverse events. Survival outcomes [overall survival (OS) and progression-free survival (PFS)] were analyzed using Kaplan-Meier survival curves. Group 1 exhibited significantly longer OS and PFS times compared with Group 4 (both P<0.05). Adverse events, including fatigue, diarrhea, nausea, vomiting and immune-related pneumonitis, were more frequent in Group 1 (all P<0.001). Group 2 also showed improved OS and PFS times compared with Group 4 (both P<0.05), with notable differences in adverse event profiles. Group 3 demonstrated superior survival outcomes compared with Group 4 (P<0.05), although with a higher incidence of adverse events. No significant differences in OS or PFS times were observed between Groups 1 and 3, or between Groups 2 and 3, indicating comparable efficacy between TACE-HAIC + lenvatinib + camrelizumab and HAIC + lenvatinib + camrelizumab. In conclusion, TACE-HAIC combined with lenvatinib and camrelizumab significantly improved both OS and PFS times in patients with HCC and PVTT compared with TACE alone, despite a higher incidence of adverse events. This combination therapy represents a promising treatment strategy for this patient population, offering enhanced survival benefits.

Keywords: hepatic arterial infusion chemotherapy; hepatocellular carcinoma; overall survival; portal vein tumor thrombosis; progression-free survival; transarterial chemoembolization.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival curves comparing (A) OS and (B) PFS between the patients with hepatocellular carcinoma treated with TACE + HAIC + lenvatinib + camrelizumab (group 1) and those treated with TACE (group 4). OS, overall survival; PFS, progression-free survival; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy.
Figure 2.
Figure 2.
Kaplan-Meier survival curves comparing (A) OS and (B) PFS between the patients with hepatocellular carcinoma treated with TACE + lenvatinib + camrelizumab (group 2) and those treated with TACE (group 4). OS, overall survival; PFS, progression-free survival; TACE, transarterial chemoembolization.
Figure 3.
Figure 3.
Kaplan-Meier survival curves comparing (A) OS and (B) PFS between the patients with hepatocellular carcinoma treated with HAIC + lenvatinib + camrelizumab (group 3) and those treated with TACE (group 4). OS, overall survival; PFS, progression-free survival; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy.
Figure 4.
Figure 4.
Kaplan-Meier survival curves comparing (A) OS and (B) PFS between the patients with hepatocellular carcinoma treated with TACE + HAIC + lenvatinib + camrelizumab (group 1) and those treated with HAIC + lenvatinib + camrelizumab (group 3). OS, overall survival; PFS, progression-free survival; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy.
Figure 5.
Figure 5.
Kaplan-Meier survival curves comparing (A) OS and (B) PFS between the patients with hepatocellular carcinoma treated with TACE + lenvatinib + camrelizumab (group 2) and those treated with HAIC + lenvatinib + camrelizumab (group 3). OS, overall survival; PFS, progression-free survival; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy.
Figure 6.
Figure 6.
Kaplan-Meier survival curves comparing (A) OS and (B) PFS between the patients with hepatocellular carcinoma treated with TACE + HAIC + lenvatinib + camrelizumab (group 1) and those treated with TACE + lenvatinib + camrelizumab (group 2). OS, overall survival; PFS, progression-free survival; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Singal A, Kanwal F, Llovet J. Global trends in hepatocellular carcinoma epidemiology: Implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864–884. doi: 10.1038/s41571-023-00825-3. - DOI - PubMed
    1. Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev. 2018;27:205–212. doi: 10.1097/CEJ.0000000000000428. - DOI - PMC - PubMed
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021;15:1295–1307. doi: 10.1080/17474124.2021.1991792. - DOI - PubMed
    1. Tao ZW, Cheng BQ, Zhou T, Gao YJ. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary Pancreat Dis Int. 2022;21:134–144. doi: 10.1016/j.hbpd.2021.12.004. - DOI - PubMed

LinkOut - more resources